Innovation Spotlight: Uterine Fibroids

In recognition of Fibroid Awareness Month this July, we take a closer look at the significant, yet often overlooked condition - uterine fibroids. Affecting a considerable number of women globally, the challenges and the numerous unmet needs in fibroid care present promising opportunities for innovators both commercially and in terms of impact.

🤓 Understanding Uterine Fibroids

Uterine fibroids, also known as leiomyomas or myomas, are noncancerous growths of the uterus that often appear during childbearing years. The exact cause of fibroids is still unclear, although there are associations with genetic changes, hormonal imbalances (high levels of estrogen and progesterone), and other growth factors.

Symptoms can vary widely. Some women might not experience any signs, while others may have heavy menstrual bleeding, periods lasting more than a week, pelvic pressure or pain, and frequent urination. The severity of these symptoms is one reason why they're so problematic, as they can severely impact a woman's quality of life.

🔬 Diagnosis and Current Treatments

Fibroids are commonly diagnosed during a pelvic exam and confirmed through imaging tests such as ultrasound, MRI, and occasionally hysteroscopy. Treatment is typically based on the size, location, and number of fibroids, as well as the woman's age, health, and whether she plans to have children in the future.

Current treatment options range from medications that regulate hormones to surgery, including hysterectomy and myomectomy, and minimally invasive procedures such as uterine artery embolization and MRI-guided focused ultrasound surgery.

While effective, these treatments often come with trade-offs. Medications can have side effects like bone loss, while surgical options may affect fertility and come with risks associated with any surgical procedure.

📊 The Scope of The Problem

Up to 80% of women will have fibroids by the age of 50, according to the U.S. Department of Health & Human Services. While not all experience symptoms, those who do often find their quality of life severely impacted.

It is estimated that 19 million women in the U.S. have uterine fibroids; an estimated 5 million women suffer from symptoms and require treatment. Black women are more likely to be diagnosed at an earlier age with uterine fibroids and are more likely to experience life-impacting symptoms.

🚀 Who's Innovating in Fibroid Diagnostics and Care?

A big need for better solutions and a big patient population have caught the attention of a handful of companies and startups that are already making strides in the area: 

Surgical Intervention

• Minerva Surgical offers a range of devices designed to treat the underlying causes of Abnormal Uterine Bleeding caused by fibroids. The company focuses on providing minimally invasive intrauterine treatments.
• Gynesonics' Sonata System combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in a non-incisional procedure for treating symptomatic uterine fibroids.
• Hologic's Acessa procedure is an outpatient, minimally invasive treatment for fibroids of all types, sizes, and locations within the uterine wall.
• Advanced Surgical Concepts' PnuemoLiner enables surgeons to perform the most minimally invasive option for tissue extraction when necessary.
• CooperSurgical develops medical devices that advance minimally invasive surgery.
• CONMED's VCare product line is used in the treatment of fibroids and endometriosis.
• Medtronic's TruClear hysteroscopic tissue removal system utilizes a mechanical approach to remove intrauterine tissue.

Medical Therapy

• Myovant's Myfembree is a medication for controlling heavy menstrual bleeding caused by uterine fibroids.
• ObsEva's Linzagolix is an orally administered GnRH receptor antagonist that potentially provides effective management of heavy menstrual bleeding associated with uterine fibroids. Linzagolix was recently acquired by Theramex.
• AbbVie's ORIAHNN is an FDA-approved oral medication designed to help reduce heavy periods caused by uterine fibroids.
• OCON, known for its intrauterine ball non-hormonal contraceptive and spherical endometrial ablation device, is exploring ways to apply its technology to the treatment of fibroids.

Digital Health

• Responsum Health aims to improve the knowledge of patients with chronic diseases, empower them to make informed healthcare decisions, and provide support and community.

🚀 Opportunities in Fibroid Diagnostics and Management

Beyond the treatments currently on or entering the market, there are several emerging technologies that hold promise for improving the diagnosis, treatment, or management of uterine fibroids:

1. Artificial Intelligence and Machine Learning: These technologies can help analyze patient data to predict fibroid growth patterns or risk, improve diagnostic accuracy, and personalize treatment plans. Algorithms can also aid in identifying patterns that humans may overlook, leading to earlier detection and intervention.
2. Genomics and Precision Medicine: Advances in genomics could lead to a better understanding of the genetic and molecular basis of fibroids. This could enable the development of precision medicines that target individual genetic profiles and disease characteristics.
3. Non-Invasive Technologies: Innovations in non-invasive diagnostic and treatment technologies can transform fibroid care. For example, high-intensity focused ultrasound (HIFU) uses sound waves to heat and destroy fibroid tissue, while advanced imaging technologies can detect fibroids early and with higher precision.
4. Digital Health Platforms: Digital platforms can enable telemedicine consultations, symptom tracking, personalized education, and virtual support. These tools empower patients to manage their health more effectively and could potentially even predict flare-ups based on symptom tracking and history.
5. Nanotechnology: Nanotechnology could allow for the targeted delivery of therapeutic agents directly to fibroid tissues. This could potentially reduce side effects and improve treatment effectiveness.
6. Regenerative Medicine and Tissue Engineering: These could potentially offer new treatment alternatives, like bioengineered uterine tissue transplants for those with severe fibroids who wish to maintain fertility.
7. Biological Therapies: This includes immunotherapies and cell-based therapies, which could offer innovative approaches to fibroid treatment.

💡 There is much room for innovation when it comes to diagnosing, treating, and managing uterine fibroids beyond the somewhat obvious medtech space. Who will be stepping up to fill the gap? We'll be paying close attention for sure!